PRDX4 overexpression is associated with poor prognosis in gastric cancer

Abstract

Peroxiredoxin IV (PRDX4) is a multifunctional protein that is involved in cell protection against oxidative injury, regulation of cell proliferation, modulation of intracellular signaling, and the pathogenesis of tumors. We previously conducted a proteomic analysis to investigate tumor-specific protein expression in gastric cancer. The aim of the present study was to investigate whether PRDX4 could be a marker of poor prognosis in patients with gastric cancer. Immunohistochemistry was used to validate PRDX4 as a prognostic marker for gastric cancer. Short hairpin RNA (shRNA)-mediated knockdown of PRDX4 expression in AGS cells and MKN28 cells was used for functional studies, and PRDX4 overexpression in PRDX4-depleted cells was used for knock-in studies. Based on immunohistochemistry data, TNM stage and PRDX4 were independent prognostic factors in the Cox proportional hazard model (P<0.05). In the survival analysis, the PRDX4-overexpressing group demonstrated significantly worse survival than the PRDX4-underexpression group (P<0.01). In vitro, knockdown of PRDX4 expression by shRNA caused a significant decrease in cancer invasion. Conversely, overexpression of PRDX4 in PRDX4-depleted cancer cells promoted migration and invasion. By measuring the expression of EMT-related genes, we found that E-cadherin was increased in shPRDX4 cells compared with control shMKN28 cells, and snail and slug were decreased in shPRDX4-1 cells compared with sh-control cells. Furthermore, the expression levels of these genes could be recovered in rescue experiments. In conclusion, the results of the present study suggested that PRDX4 is a marker of poor prognosis in gastric cancer and that PRDX4 is associated with cancer cell migration and invasion via EMT.

Validation of the interaction between PRDX4 and TXNDC5 in gastric cancer and the significance of the PRDX4 gene in gastric cancer based on a data mining analysis

“…In relation to the data from TCGA database, the R language analysis results showed that the survival time of patients with high expressions of the PRDX4 gene was not significantly different from that of patients with low expressions of the gene (P>0.05). Conversely, Park et al ’s research findings ( 12 ) suggest that the survival time of patients with high expressions of the PRDX4 gene was significantly lower than that of patients with low expressions of the gene (P<0.05) ( Figure 9 ).…”

“…A P value <0.05 was considered statistically significant. Additionally, we used the survival curve of PRDX4 and gastric cancer in Park et al ’s study as an auxiliary explanation ( 12 ).…”

To Explore Genes Related to the Prognosis of Colorectal Cancer

“…They suggest PALB2 mutations predispose specifically to aggressive prostate cancers [30] . PRDX4 belongs to the typical 2-Cys PRDXs group and involved cell protection against oxidative injury, regulation of cell proliferation, modulation of intracellular signaling and the pathogenesis of tumors [31] . The PRDX4 show overexpression in many tumors.…”

Single-Cell Transcriptional and Epigenetic Profiles of Male Breast Cancer Nominate Salient Cancer-Specific Enhancers

“…Since ANXA2 expression is even higher in MBC, our enhancer-promoter interaction model may provide a way to understand the mechanism by which MBC becomes resistance to standard therapy. Similarly, PRDX4 is overexpressed in several cancers such as gastric cancer 65 , lung cancer 66 , and breast cancer 54 . In addition, elevated PRDX4 expression is associated with worse overall and disease-free survival in female breast cancer patients 54 .…”